T1	Participants 50 78	Primary Biliary Cholangitis.
T2	Participants 91 162	Primary biliary cholangitis (formerly called primary biliary cirrhosis)
T3	Participants 451 641	12-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable
T4	Participants 1027 1129	216 patients who underwent randomization and received at least one dose of obeticholic acid or placebo
T5	Participants 2309 2353	in patients with primary biliary cholangitis
